Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation

T. E. Raya, R. G. Gray, Steven Goldman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The hemodynamic effects of selective inhibition of arginine vasopressin (AVP) with a V1 antagonist, (CH2)5yreAVPa CL-1-4A, were studied in normal rats (n = 17) and in rats 4 weeks after coronary artery ligation with large myocardial infarctions and elevated left ventricular end-diastolic pressures (n = 22). In normal rats AVP inhibition with a 35-μg/kg bolus of AVP V1 antagonist did not change heart rate, right atrial, left ventricular systolic, left ventricular end-diastolic or aortic pressures. There were also no changes in mean circulatory filling pressure, unstressed vascular volume, blood volume or venous compliance. In rats with infarction and elevated left ventricular end-diastolic pressures, AVP inhibition did not change heart rate, right atrial pressure, mean circulatory filling pressure or blood volume, but mean aortic pressure decreased from 103 ± 3 to 88 ± 2 mm Hg (P < .001), venous compliance increased (P < .001) from 2.17 ± 0.07 to 3.04 ± 0.11 ml/mm Hg/kg and unstressed vascular volume decreased from 42.3 ± 3.1 to 34.7 ± 2.6 ml/kg (P < .05). We conclude that inhibition of AVP with a specific V1 antagonist had no effect on the venous or arterial circulations in normal rats, but in rats with left ventricular dysfunction and heart failure after chronic myocardial infarction, AVP inhibition decreased arterial pressure and caused venodilatation.

Original languageEnglish (US)
Pages (from-to)1015-1020
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume255
Issue number3
StatePublished - 1990
Externally publishedYes

Fingerprint

Arginine Vasopressin
Vasopressins
Heart Failure
Arterial Pressure
Blood Pressure
Blood Volume
Compliance
Blood Vessels
Heart Rate
Myocardial Infarction
Pressure
Atrial Pressure
Left Ventricular Dysfunction
Infarction
Ligation
Coronary Vessels
Hemodynamics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation. / Raya, T. E.; Gray, R. G.; Goldman, Steven.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 255, No. 3, 1990, p. 1015-1020.

Research output: Contribution to journalArticle

@article{27a3062de0ce44a0a526e6e7bb207fee,
title = "Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation",
abstract = "The hemodynamic effects of selective inhibition of arginine vasopressin (AVP) with a V1 antagonist, (CH2)5yreAVPa CL-1-4A, were studied in normal rats (n = 17) and in rats 4 weeks after coronary artery ligation with large myocardial infarctions and elevated left ventricular end-diastolic pressures (n = 22). In normal rats AVP inhibition with a 35-μg/kg bolus of AVP V1 antagonist did not change heart rate, right atrial, left ventricular systolic, left ventricular end-diastolic or aortic pressures. There were also no changes in mean circulatory filling pressure, unstressed vascular volume, blood volume or venous compliance. In rats with infarction and elevated left ventricular end-diastolic pressures, AVP inhibition did not change heart rate, right atrial pressure, mean circulatory filling pressure or blood volume, but mean aortic pressure decreased from 103 ± 3 to 88 ± 2 mm Hg (P < .001), venous compliance increased (P < .001) from 2.17 ± 0.07 to 3.04 ± 0.11 ml/mm Hg/kg and unstressed vascular volume decreased from 42.3 ± 3.1 to 34.7 ± 2.6 ml/kg (P < .05). We conclude that inhibition of AVP with a specific V1 antagonist had no effect on the venous or arterial circulations in normal rats, but in rats with left ventricular dysfunction and heart failure after chronic myocardial infarction, AVP inhibition decreased arterial pressure and caused venodilatation.",
author = "Raya, {T. E.} and Gray, {R. G.} and Steven Goldman",
year = "1990",
language = "English (US)",
volume = "255",
pages = "1015--1020",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation

AU - Raya, T. E.

AU - Gray, R. G.

AU - Goldman, Steven

PY - 1990

Y1 - 1990

N2 - The hemodynamic effects of selective inhibition of arginine vasopressin (AVP) with a V1 antagonist, (CH2)5yreAVPa CL-1-4A, were studied in normal rats (n = 17) and in rats 4 weeks after coronary artery ligation with large myocardial infarctions and elevated left ventricular end-diastolic pressures (n = 22). In normal rats AVP inhibition with a 35-μg/kg bolus of AVP V1 antagonist did not change heart rate, right atrial, left ventricular systolic, left ventricular end-diastolic or aortic pressures. There were also no changes in mean circulatory filling pressure, unstressed vascular volume, blood volume or venous compliance. In rats with infarction and elevated left ventricular end-diastolic pressures, AVP inhibition did not change heart rate, right atrial pressure, mean circulatory filling pressure or blood volume, but mean aortic pressure decreased from 103 ± 3 to 88 ± 2 mm Hg (P < .001), venous compliance increased (P < .001) from 2.17 ± 0.07 to 3.04 ± 0.11 ml/mm Hg/kg and unstressed vascular volume decreased from 42.3 ± 3.1 to 34.7 ± 2.6 ml/kg (P < .05). We conclude that inhibition of AVP with a specific V1 antagonist had no effect on the venous or arterial circulations in normal rats, but in rats with left ventricular dysfunction and heart failure after chronic myocardial infarction, AVP inhibition decreased arterial pressure and caused venodilatation.

AB - The hemodynamic effects of selective inhibition of arginine vasopressin (AVP) with a V1 antagonist, (CH2)5yreAVPa CL-1-4A, were studied in normal rats (n = 17) and in rats 4 weeks after coronary artery ligation with large myocardial infarctions and elevated left ventricular end-diastolic pressures (n = 22). In normal rats AVP inhibition with a 35-μg/kg bolus of AVP V1 antagonist did not change heart rate, right atrial, left ventricular systolic, left ventricular end-diastolic or aortic pressures. There were also no changes in mean circulatory filling pressure, unstressed vascular volume, blood volume or venous compliance. In rats with infarction and elevated left ventricular end-diastolic pressures, AVP inhibition did not change heart rate, right atrial pressure, mean circulatory filling pressure or blood volume, but mean aortic pressure decreased from 103 ± 3 to 88 ± 2 mm Hg (P < .001), venous compliance increased (P < .001) from 2.17 ± 0.07 to 3.04 ± 0.11 ml/mm Hg/kg and unstressed vascular volume decreased from 42.3 ± 3.1 to 34.7 ± 2.6 ml/kg (P < .05). We conclude that inhibition of AVP with a specific V1 antagonist had no effect on the venous or arterial circulations in normal rats, but in rats with left ventricular dysfunction and heart failure after chronic myocardial infarction, AVP inhibition decreased arterial pressure and caused venodilatation.

UR - http://www.scopus.com/inward/record.url?scp=0025684637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025684637&partnerID=8YFLogxK

M3 - Article

VL - 255

SP - 1015

EP - 1020

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -